INGN / Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wal more_horizontal

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock. more_horizontal

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis m more_horizontal

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances. more_horizontal

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considerin more_horizontal

Inogen, Inc. (NASDAQ:INGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Agnes Lee - Senior Vice President, Investo more_horizontal

Inogen (INGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.02 more_horizontal

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growi more_horizontal